Biotech Stocks in “Total Eclipse” as Financial Pressures Mount

More than a year after biotech stock indices peaked, the markets are worse than ever. Meanwhile, rumors of an impending wave of opportunistic biotech acquisitions are yet to materialize.

In February of last year, biotech stocks across Europe and the US saw the end of a pandemic-fuelled…

Source: www.labiotech.eu – Read more